Two months after filing with the US FDA, embattled generics giant Teva Pharmaceutical Industries’ (NYSE: TEVA) has been given priority review and fast track designation for fremanezumab, a novel biologic for the preventive treatment of migraine.
The candidate is part of a novel class of monoclonal antibodies called anti-calcitonin gene-related peptides (anti-CGRP), thought to have potential in a therapeutic area which has a high level of unmet need.
The market for migraine treatments is expected to grow to up to $9 billion by 2026, boosted by the anticipated approval of such therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze